IncFact
Company Profiles: Revenue, Growth, Competition

TETRAPHASE PHARMACEUTICALS Revenue, Growth & Competitor Profile

Last updated:

Company Awards

 
Public Company
public company
Fast Growing
Fastest Growing
Brain Power (IP)
Patent/Trademark IP
 

Company Profile & Annual Report for Tetraphase Pharmaceuticals

Access the complete profile.

Tetraphase Pharmaceuticals Fast Facts

Revenue$1 - $10 million    See Exact Annual Revenue
Employees100 - 500Exact Company Size
Primary Industry325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes32541
325412 Pharmaceutical Preparation Manufacturing
541711 Research & Development in Biotechnology
Address480 Arsenal Way
Suite 110
Watertown, MA 02472

www.tphase.com


Tetraphase Pharmaceuticals's annual revenues are $1-$10 million (see exact revenue data) and has 100-500 employees. It is classified as operating in the Medicinal & Botanical Manufacturing industry.


Tetraphase Pharmaceuticals's Annual Report & Profile shows critical firmographic facts:
  • What is the company's size? (Annual sales and employees)
  • What industry is the company in?

Tetraphase Pharmaceuticals is a publicly traded company on NMS using the ticker symbol TTPH. Detailed information on company financials and operating reports can be found here: NMS: TTPH



Tetraphase Pharmaceuticals Annual Revenue and Growth Rate

Tetraphase Pharmaceuticals Revenue Est.
($ Million)
Growth Rate (%)# Employees
2018 Details in Premium Report
2017
2016
2015
2014
2013


1-Year Growth Rate:
3-Year Growth Rate (CAGR):
Premium Report

Note: Tetraphase Pharmaceuticals's revenues are gauged from an analysis of company filings.



Investor Activity

Tetraphase Pharmaceuticals has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.

Date Investors Percent Raised Target Size
January 28, 2020 1 100%$10 MM
Complete list of funding rounds and total amounts in the Company Report




Trademark Applications

Trademark applications show the products and services that Tetraphase Pharmaceuticals is developing and marketing. Tetraphase Pharmaceuticals doesn't have any recent trademark applications, indicating Tetraphase Pharmaceuticals is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark Date
XERAVA
Pharmaceutical preparations, namely, antibiotics
02/02/2018
XRAVA
Pharmaceutical preparations, namely, antibiotics
02/02/2018
XYRAVIO
Pharmaceutical preparations, namely, antibiotics; all of the foregoing excluding pharmaceutical preparations and substances for the treatment and/or management of, the central nervous system, sleep disorders, cognitive disorders, fibromyalgia, insomnia, narcolepsy, and neurological or psychiatric diseases or disorders
12/11/2015

See all trademarks and details in the Full Report.


Recession Risk

Determine whether Tetraphase Pharmaceuticals grew or shrank during the last recession. This is useful in estimating the financial strength and credit risk of the company. Compare how recession-proof Tetraphase Pharmaceuticals is relative to the industry overall. While a new recession may strike a particular industry, measuring the industry and company's robustness during the last recession estimates its ability to weather future recessions.



U.S. Industry Overview & Market Statistics:
Medicinal & Botanical Manufacturing

Publisher: AnythingResearch

  • Market Size
  • Growth Rate
  • 5-Year Market Forecast
  • Average Company Size & Growth
  • Salary & Compensation Benchmarks



Market Share of Tetraphase Pharmaceuticals's Largest Competitors

A competitive analysis shows these companies are in the same general field as Tetraphase Pharmaceuticals, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company HeadquartersRevenue ($ MM)
TMUNITY THERAPEUTICSPhiladelphia, PA100 
PANACEA BIOMATXResearch Triangle Park, NC52 




Nearby Competitors

These companies are similar in business line and location to Tetraphase Pharmaceuticals. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company HeadquartersRevenue ($ MM)
BIOGEN U.S.Weston, MA100 
SHIRE HOLDINGS US AGLexington, MA73 
CUBIST PHARMACEUTICALSLexington, MA7 
BIOVERATIVWaltham, MA7 
AMAG PHARMACEUTICALSWaltham, MA4 
REPLIGENWaltham, MA1 




Future Competition: Tetraphase Pharmaceuticals's Fastest Growing Competitors

These companies are in the same general field as Tetraphase Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

CompanyRevenue ($ MM)
Tetraphase Pharmaceuticals Competitors